Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21787700 | 0.83 | MEN1 (0.37) | MEN1KMT2ASCARB1P2RX3PKM | |
| SCHEMBL15508908 | 0.75 | GLS (0.55) | MEN1KMT2ASCARB1ALDH1A1MAPT | |
| SCHEMBL22421774 | 0.74 | BRPF1 (0.45) | MEN1KMT2AALDH1A1P2RX3KDM4C | |
| SCHEMBL21787628 | 0.73 | PARG (0.43) | ALDH1A1MAPTHSP90AA1CCR2 | |
| SCHEMBL21787679 | 0.73 | CFTR (0.48) | MEN1KMT2AALDH1A1MAPTCCR2 | |
| SCHEMBL3648701 | 0.72 | SIRT2 (0.37) | MEN1KMT2ASCARB1ALDH1A1MAPT | |
| SCHEMBL7522783 | 0.71 | MEN1 (0.45) | MEN1KMT2AMAPTKDM4CNPC1 | |
| SCHEMBL15244052 | 0.71 | MEN1 (0.39) | MEN1KMT2AALDH1A1MAPTP2RX3 | |
| SCHEMBL21774723 | 0.70 | CYP1A2 (0.57) | MEN1KMT2AMAPTCCR2SMN1; SMN2 | |
| SCHEMBL21774721 | 0.70 | MAPT (0.50) | ALDH1A1MAPTCCR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| EP-3555063-B1 | 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BCL6, BCL6B, BCOR | MEN1 1802/4885KMT2A 216/4885SCARB1 3195/4885 |
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BCL6, BCL6B, BCOR | MEN1 1315/4885KMT2A 229/4885SCARB1 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.